Dingxiao Zhang

Affiliated Hospital of Hunan University, Hunan University

Research Area

Biography

Dingxiao Zhang has not added Biography.
If you are Dingxiao Zhang and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2026

Other Publications

Article	Year
Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Nature communications\| PubMed ID: 32350277	2020
RBM38 in cancer: role and mechanism. Cellular and molecular life sciences : CMLS\| PubMed ID: 32642788	2021
The spliceosome as a new therapeutic vulnerability in aggressive prostate cancer. Molecular & cellular oncology\| PubMed ID: 32944637	2020
Genetically engineered oncolytic bacteria as drug delivery systems for targeted cancer theranostics. Acta biomaterialia\| PubMed ID: 33561563	2021
Integrins regulate stemness in solid tumor: an emerging therapeutic target. Journal of hematology & oncology\| PubMed ID: 34715893	2021
A mAvalue predictive of prostate cancer stemness, tumor immune landscape and immunotherapy response. NAR cancer\| PubMed ID: 35350771	2022
Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia. The Journal of clinical investigation\| PubMed ID: 35900794	2022
YY1 complex in M2 macrophage promotes prostate cancer progression by upregulating IL-6. Journal for immunotherapy of cancer\| PubMed ID: 37094986	2023
Prostate Cancer Progression Relies on the Mitotic Kinase Citron Kinase. Cancer research\| PubMed ID: 37801613	2023
An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a tumor suppressive role in aggressive prostate cancer. Oncogene\| PubMed ID: 38565944	2024
Identification of an anaplastic subtype of prostate cancer amenable to therapies targeting SP1 or translation elongation. Science advances\| PubMed ID: 38569039	2024
A Stapled Peptide Inhibitor Targeting the Binding Interface of N6-Adenosine-Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy. Angewandte Chemie (International ed. in English)\| PubMed ID: 38607929	2024
Peptide Degrader-Based Targeting of METTL3/14 Improves Immunotherapy Response in Cutaneous Melanoma. Angewandte Chemie (International ed. in English)\| PubMed ID: 39136347	2024
Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy. Cancer letters\| PubMed ID: 39218291	2024
Stabilization of RRBP1 mRNA via an mA-dependent manner in prostate cancer constitutes a therapeutic vulnerability amenable to small-peptide inhibition of METTL3. Cellular and molecular life sciences : CMLS\| PubMed ID: 39367907	2024
Comprehensive Characterization of the Integrin Family Across 32 Cancer Types. Genomics, proteomics & bioinformatics\| PubMed ID: 39436262	2024
Circadian disruption in cancer and regulation of cancer stem cells by circadian clock genes: An updated review. Cancer letters\| PubMed ID: 39672457	2024
Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival. bioRxiv : the preprint server for biology\| PubMed ID: 40458374	2025
YY1 enhances HIF-1α stability in tumor-associated macrophages to suppress anti-tumor immunity of prostate cancer in mice. Nature communications\| PubMed ID: 40623999	2025
Rbm38 deficiency impairs erythroid heme biosynthesis and induces porphyria via reduced ferrochelatase expression. Blood\| PubMed ID: 40961234	2025
A conserved eIF1A luminal cell-centered hypoxic and "cold" tumor microenvironment promotes pan-subtype prostate cancer progression. Cell reports. Medicine\| PubMed ID: 41707646	2026